Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
Despite the plethora of clinical drug trials in tardive dyskinesia, few consistent findings have emerged. One possible reason for this is that there have been no serious attempts to define the role of major neurotransmitter systems (dopamine, norepinephrine, acetylcholine, serotonin, GABA) in one specific population of tardive dyskinesia patients. This study reports a series of five controlled drug trials in a population of patients with persistent tardive dyskinesia; each drug probed one of four neurotransmitter systems. The intra- and interpatient responses are analyzed and the implications of the pharmacologic response profiles for the clinical management of tardive dyskinesia are discussed.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002794:Choline / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008781:Methyltyrosines / Q000627:therapeutic use*; D008875:Middle Aged; D009638:Norepinephrine / Q000502:physiology; D010919:Placebos; D009435:Synaptic Transmission / Q000187:drug effects; D014635:Valproic Acid / Q000627:therapeutic use*
D008781:Methyltyrosines; D010919:Placebos; D014635:Valproic Acid; D004295:Dihydroxyphenylalanine; D006916:5-Hydroxytryptophan; D002794:Choline; D004298:Dopamine; D009638:Norepinephrine